Veeva Systems Inc.
VEEV Healthcare Health Information Services
Veeva Systems Inc.’s revenue for fiscal 2026 (year ended January 2026) was $3.2 billion, up 16.3% from fiscal 2025. In the quarter to July 2026, revenue grew 17.6%, EPS grew 36.6% and free cash flow was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for ten.
Follow VEEV
Veeva Systems Inc. (VEEV) P/S ratio
As of 16 October 2026, Veeva Systems Inc. (VEEV) trades at a P/S ratio of 14.6×. Over the past ten years it has ranged from 6.6× (February 2016) to 36.2× (October 2020); the current reading is higher than 55% of that period. That is above the Health Information Services industry median of 2.2× and above the Healthcare sector median of 3.4×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2026 | 10.4× | (24.24%) |
| FY2025 | 13.7× | (2.40%) |
| FY2024 | 14.1× | 14.55% |
| FY2023 | 12.3× | (37.22%) |
| FY2022 | 19.6× | (32.68%) |
| FY2021 | 29.1× | 48.24% |
| FY2020 | 19.6× | 7.57% |
| FY2019 | 18.2× | 42.85% |
| FY2018 | 12.8× | 22.42% |
| FY2017 | 10.4× | 32.82% |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Jul 2026 | 9.6× | 24.64% |
| Apr 2026 | 7.7× | (26.31%) |
| Jan 2026 | 10.4× | (32.84%) |
| Oct 2025 | 15.5× | (0.93%) |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| BTSG BrightSpring Health Services, Inc. compare | 0.9× |
| WAY Waystar Holding Corp. compare | 4.4× |
| HQY HealthEquity, Inc. compare | 5.6× |
| TEM Tempus AI, Inc. compare | 8.1× |
| DOCS Doximity, Inc. compare | 8.6× |
| HNGE Hinge Health Inc. compare | 10.9× |
| VEEV Veeva Systems Inc. | 14.6× |
| TXG 10x Genomics compare | 14.7× |
| HTFL Heartflow, Inc. compare | 19.7× |
| Health Information Services industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on VEEV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement